Creabilis

company

About

Creabilis, a specialty pharmaceutical company focused on dermatology, discovers and develops new medicines for a range of skin disorders.

  • 1 - 10

Details

Last Funding Type
Series B
Last Funding Money Raised
$20M
Industries
Biotechnology,Health Care,Pharmaceutical
Founded date
Jan 1, 2003
Number Of Employee
1 - 10
Operating Status
Close

Creabilis is an emerging European specialty pharmaceutical company focused on dermatology. Creabilis discovers, develops and commercialises new medicines for a range of skin disorders, - an area of significant unmet medical need and high commercial potential.

Creabilis has an exceptional track record in dermatological research and has used this experience to generate a rich pipeline of clinical and pre-clinical drug candidates that the company will market directly or in partnership. The most advanced product is CT327 for the treatment of psoriasis. CT327 will enter Phase II clinical trials in 2009. Creabilis' pipeline also includes a number of pre-clinical drug candidates arising from its ground breaking drug discovery programmes.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
$20M
Creabilis has raised a total of $20M in funding over 2 rounds. Their latest funding was raised on Oct 4, 2011 from a Series B round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Oct 4, 2011 Series B $20M 1 Abbott Biotech Ventures Detail

Investors

Number of Lead Investors
Number of Investors
1
1
Creabilis is funded by 1 investors. Abbott Biotech Ventures are the most recent investors.
Investor Name Lead Investor Funding Round
Abbott Biotech Ventures Yes Series B